Seres Therapeutics Restructures Operations, Cuts Jobs Amid Pipeline Concerns

Seres Therapeutics Inc. (NASDAQ:MCRB) has announced a significant shift in its operational strategy, leading to a sharp decline in its stock price during Thursday’s premarket session. The company’s shares fell by 16.25%, trading at $11.80, as investors reacted to the decision to pause investments in its lead drug program while focusing on earlier-stage projects.

This strategic pivot comes as Seres aims to prioritize emerging programs targeting inflammatory and immune diseases. The move has raised concerns regarding the viability of its current drug pipeline and funding strategies.

Focus on Early-Stage Programs

Seres has finalized the protocol for its Phase 2 study of SER-155, aimed at patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT). While the company has paused further investments in this program, it is actively seeking funding to support its Phase 2 study. Alongside this, Seres plans to back the read-out of clinical results from the Investigator-sponsored SER-155 study in immune checkpoint-related enterocolitis (irEC), with results anticipated in the early second quarter of 2026.

The company intends to concentrate on advancing its early-stage programs, particularly SER-603, which targets inflammatory conditions such as ulcerative colitis and Crohn’s disease. Ongoing discussions with potential collaborators may open avenues for funding and partnerships in these areas.

While this shift could present new opportunities, it has also sparked uncertainty regarding Seres Therapeutics’ immediate future and operational sustainability.

Workforce Reduction and Financial Outlook

In conjunction with these strategic changes, Seres Therapeutics announced a workforce reduction of approximately 30% to extend its cash runway through the third quarter of 2026. This decision aims to allow the company to focus on its early-stage live biotherapeutic programs and pursue potential collaborations. With a cash balance of $47.6 million, Seres anticipated funding its operations through the second quarter of 2026.

Despite a generally positive market environment—with the Nasdaq gaining 0.32% and S&P 500 futures rising 0.3%—Seres’s stock decline highlighted company-specific concerns affecting its performance.

Technical indicators reflect a bearish trend for Seres Therapeutics, with the stock trading 24.4% below its 20-day simple moving average (SMA) and 33% below its 100-day SMA. Over the past year, the stock has decreased by 13.86% and is closer to its 52-week lows than highs, illustrating ongoing challenges in its operational strategy. As of now, the Relative Strength Index (RSI) stands at 42.50, indicating neutral territory, while the Moving Average Convergence Divergence (MACD) is below its signal line, suggesting continued bearish pressure.

Key resistance for the stock is noted at $13.50, with support identified at $11.00.

The future trajectory of Seres Therapeutics will depend on its ability to secure funding and effectively navigate these operational challenges, as it seeks to revitalize its drug development pipeline.